Use of myeloid cell biomarkers for the diagnosis of cancer

Patent metadata

Field	Value
Publication number	US-9671404-B2
Application number	US-201113239011-A
Country	US
Kind code	B2
Filing date	Sep 21, 2011
Priority date	Sep 21, 2010
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.

First claim

The invention claimed is:

1. A method for treating a patient suffering from metastatic renal cell carcinoma or metastatic adenocarcinoma that has been pretreated with cyclophosphamide, comprising:
a) obtaining a biological sample comprising peripheral blood mononuclear cells (PBMC) from said patient;
b) contacting the biological sample with a detectably-labeled antibody specific for CD11b, a detectably-labeled antibody specific for CD14, a detectably-labeled antibody specific for CD15, a detectably-labeled antibody specific for CD80, a detectably-labeled antibody specific for CD83, a detectably-labeled antibody specific for CD86, and a detectably-labeled antibody specific for HLA-DR;
c) quantitating the level of myeloid-derived suppressor cells having MDSC5 phenotype in the patient relative to the level of myeloid-derived suppressor cells having MDSC5 phenotype in a non-treated patient sample by flow cytometry, wherein said MDSC5 phenotype is based on markers CD11b+, CD14−, CD15+, FSChi, SSCim, CD80−, CD83−, CD86−, and HLA-DR-; and
d) administering an anti-cancer vaccine to said patient if the level of myeloid-derived suppressor cells having MDSC5 phenotype from step (c) is decreased compared to a non-treated patient sample, wherein said anti-cancer vaccine is selected from an anti-cancer vaccine comprising a mixture of immunogenic peptides having a sequence selected from SEQ ID No. 1 to 10; SEQ ID No. 11 to 19 and 1, 5, 8, and 9; SEQ ID No. 20 to 29, and SEQ ID No. 30 to 37.

2. The method according to claim 1 , wherein said method comprises flow cytometry comprising a single multicolor staining step.

3. The method according to claim 1 , wherein said biological sample is selected from the group consisting of whole blood, peripheral blood, or fractions thereof, buffy coat, tumor tissue, and bone marrow.

4. The method of claim 1 , wherein said patient has been pretreated with cyclophosphamide.

5. The method of claim 1 , wherein said anti-cancer vaccine is administered together with GM-CSF.

Assignees

• Singh Harpreet
• Mendrzyk Regina
• Walter Steffan
• Bronte Vincezq
• Mandruzzato Susanna
• Immatics Biotechnologies Gmbh

Inventors

• Singh Harpreet
• Mendrzyk Regina
• Walter Steffan
• Bronte Vincezq
• Mandruzzato Susanna

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• G01N33/53

  Immunoassay; Biospecific binding assay; Materials therefor · CPC title

• G01N33/00

  Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00 · CPC title

• G01N33/5047

  Cells of the immune system · CPC title